Who are Changkang granules's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Standard treatment+Xiyanping injection, XueBiJing Injection, Yunnan Baiyao, Songling Xuemaikang Capsules, Compound Ciwujia Granules, Abelmoschus manihot (AM).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/changkang-granules.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Changkang granules — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Changkang granules (Changkang granules) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Traditional Chinese medicine. Area: Gastroenterology.

phase 3 Traditional Chinese medicine Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Changkang granules (Changkang granules) — Tasly Pharmaceutical Group Co., Ltd. Changkang granules is a traditional Chinese medicine formulation that promotes gastrointestinal motility and improves digestive function.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Changkang granules TARGET	Changkang granules	Tasly Pharmaceutical Group Co., Ltd	phase 3	Traditional Chinese medicine
Standard treatment+Xiyanping injection	Standard treatment+Xiyanping injection	Jiangxi Qingfeng Pharmaceutical Co. Ltd.	marketed	Traditional Chinese medicine extract
XueBiJing Injection	XueBiJing Injection	Nanjing Medical University	marketed	Herbal extract / Traditional Chinese Medicine
Yunnan Baiyao	Yunnan Baiyao	Peking University Third Hospital	marketed	Traditional Chinese medicine / Herbal preparation
Songling Xuemaikang Capsules	Songling Xuemaikang Capsules	Xiyuan Hospital of China Academy of Chinese Medical Sciences	marketed	Traditional Chinese medicine herbal formulation
Compound Ciwujia Granules	Compound Ciwujia Granules	Shanghai Municipal Hospital of Traditional Chinese Medicine	marketed	Traditional Chinese medicine herbal formulation
Abelmoschus manihot (AM)	Abelmoschus manihot (AM)	Chinese PLA General Hospital	marketed	Herbal extract / Traditional Chinese Medicine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Traditional Chinese medicine class)

Shanghai University of Traditional Chinese Medicine · 2 drugs in this class
Jiangsu Famous Medical Technology Co., Ltd. · 2 drugs in this class
Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 1 drug in this class
Sichuan Jishengtang Pharmaceutical Co., Ltd. · 1 drug in this class
Tasly Pharmaceutical Group Co., Ltd · 1 drug in this class
China Academy of Chinese Medical Sciences · 1 drug in this class
The First Affiliated Hospital of Guangzhou Medical University · 1 drug in this class
Dongzhimen Hospital, Beijing · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Changkang granules — Competitive Intelligence Brief. https://druglandscape.com/ci/changkang-granules. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab